Study reports Alzheimer’s treatment gains in long-term care

Top-line data from a real-world study suggest that Zunveyl (benzgalantamine) was associated with provider-reported improvements in cognition, behavioral symptoms, daily functioning, and overall treatment experience in people with mild-to-moderate Alzheimer’s disease.

The BEACON study evaluated provider-reported outcomes from 21 investigators treating 162 long-term care patients who received routine clinical care with Zunveyl for three months to a year.

“We believe that long-term care patients with Alzheimer’s disease remain underrepresented in traditional clinical datasets despite representing a significant and clinically complex treatment population,” Michael McFadden, CEO of Alpha Cognition, the company that developed Zunveyl, said in a company press release. “BEACON provides valuable real-world insights into the treatment experience of long-term care patients with Alzheimer’s disease receiving ZUNVEYL.”

Erik Cabrera, MD, board-certified psychiatrist and long-term care practitioner, added that “the importance of the BEACON study lies in its focus on the patients we care for every day in long-term care facilities—individuals with Alzheimer’s disease whose cognitive decline is often accompanied by neuropsychiatric symptoms, functional impairment, and substantial medication burden.”